Glucocerebrosidase mutations in subjects with parkinso

Molecular Genetics and Metabolism
81, 70-73
DOI: 10.1016/j.ymgme.2003.11.004

Citation Report

#	Article	IF	Citations
1	Parkinsonism among Gaucher disease carriers. Journal of Medical Genetics, 2004, 41, 937-940.	3.2	320
2	Gaucher disease: complexity in a â€œsimpleâ€•disorder. Molecular Genetics and Metabolism, 2004, 83, 6-15.	1.1	350
3	Molecular genetic pathways in Parkinson's disease: a review. Clinical Science, 2005, 109, 355-364.	4.3	37
4	Gaucher disease: pathological mechanisms and modern management. British Journal of Haematology, 2005, 129, 178-188.	2.5	240
5	The emerging field of lipidomics. Nature Reviews Drug Discovery, 2005, 4, 594-610.	46.4	1,104
6	Analysis of the glucocerebrosidase gene in Parkinson's disease. Movement Disorders, 2005, 20, 367-370.	3.9	107
7	Pilot association study of the Î²-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Movement Disorders, 2005, 20, 100-103.	3.9	93
8	Neurodegenerative Disorders: The Role of Genetic Factors in Their Origin and the Efficiency of Treatment. Human Physiology, 2005, 31, 472-482.	0.4	3
9	Study of Multimodal Evoked Potentials in Patients With Type 1 Gaucher's Disease. Journal of Child Neurology, 2005, 20, 124-128.	1.4	15
10	The Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews. New England Journal of Medicine, 2005, 352, 728-731.	27.0	90
11	LRRK2 gene in Parkinson disease. Neurology, 2005, 65, 696-700.	1.1	160
12	Mutations in the glucocerebrosidase gene and Parkinson disease: Phenotypeâ€“genotype correlation:. Neurology, 2005, 65, 1460-1461.	1.1	74
13	Hematologically important mutations: Gaucher disease. Blood Cells, Molecules, and Diseases, 2005, 35, 355-364.	1.4	154
14	Gaucher disease and parkinsonism. Molecular Genetics and Metabolism, 2005, 84, 302-304.	1.1	75
15	Nosology of Parkinsonâ€™s Disease: Looking for the Way Out of a Quackmire. Neuron, 2005, 47, 479-482.	8.1	87
16	A Chaperone-Mediated Approach to??Enzyme Enhancement as a Therapeutic Option for the Lysosomal??Storage Disorders. Drugs in R and D, 2006, 7, 339-348.	2.2	19
17	Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology, 2006, 67, 908-910.	1.1	204
19	From genes to systems: New global strategies for the characterization of NCL biology. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 934-944.	3.8	14

#	Article	IF	Citations
20	Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells, Molecules, and Diseases, 2006, 36, 426-428.	1.4	118
21	Detection of 12 new mutations in Gaucher disease Brazilian patients. Blood Cells, Molecules, and Diseases, 2006, 37, 204-209.	1.4	22
22	Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism. Neuroscience Letters, 2006, 404, 163-165.	2.1	14
23	Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clinical Genetics, 2006, 70, 275-282.	2.0	53
24	Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Movement Disorders, 2006, 21, 282-283.	3.9	64
25	Self-stimulatory behavior associated with deep brain stimulation in Parkinson's disease. Movement Disorders, 2006, 21, 283-285.	3.9	34
26	Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology, 2006, 66, 415-417.	1.1	96
27	Gaucher Disease and the Synucleinopathies. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-6.	3.0	45
28	Lewy bodies. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1661-1668.	7.1	401
29	Parkinsons Disease: Genetics and Beyond. Current Neuropharmacology, 2007, 5, 99-113.	2.9	28
31	Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology, 2007, 69, 1270-1277.	1.1	226
32	Glucocerebrosidase Mutations and Risk of Parkinson Disease in Chinese Patients. Archives of Neurology, 2007, 64, 1056.	4.5	84
33	Genetics of Parkinson disease. Genetics in Medicine, 2007, 9, 801-811.	2.4	101
34	Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Molecular Genetics and Metabolism, 2007, 91, 195-200.	1.1	111
36	GM1 Specifically Interacts with Î±-Synuclein and Inhibits Fibrillation. Biochemistry, 2007, 46, 1868-1877.	2.5	239
37	Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Movement Disorders, 2007, 22, 1481-1484.	3.9	103
38	Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene. Movement Disorders, 2007, 22, 932-937.	3.9	16
39	Movement and mood disorder in two brothers with Gaucher disease. Clinical Genetics, 2007, 72, 357-361.	2.0	10

#	Article	IF	Citations
40	â€˜Nonâ€neuronopathicâ€™ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. Journal of Inherited Metabolic Disease, 2008, 31, 337-349.	3.6	79
41	Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Movement Disorders, 2008, 23, 460-463.	3.9	83
42	Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. FEBS Journal, 2008, 275, 5767-5773.	4.7	121
43	Treating patients with Gaucher disease and parkinsonism: Misrepresentation in a title. Parkinsonism and Related Disorders, 2008, 14, 81-82.	2.2	3
44	Association between Parkinson's disease and glucocerebrosidase mutations in Brazil. Parkinsonism and Related Disorders, 2008, 14, 58-62.	2.2	62
45	The Need for Appropriate Genotyping Strategies for Glucocerebrosidase Mutations in Cohorts With Parkinson Disease. Archives of Neurology, 2008, 65, 849.	4.5	17
46	Glucocerebrosidase Gene Mutations. Archives of Neurology, 2008, 65, 379-82.	4.5	188
47	The Spectrum of Parkinsonian Manifestations Associated With Glucocerebrosidase Mutations. Archives of Neurology, 2008, 65, 1353-7.	4.5	170
48	Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology, 2008, 70, 2277-2283.	1.1	334
49	Gaucher and Parkinson diseases. Neurology, 2008, 70, 2272-2273.	1.1	24
50	Progress in the pathogenesis and genetics of Parkinson's disease. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 2215-2227.	4.0	63
51	Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics: Targets and Therapy, 0, , 407.	3.2	7
53	Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects. Genetics in Medicine, 2009, 11, 139-146.	2.4	186
54	Mutations for Gaucher Disease Confer High Susceptibility to Parkinson Disease. Archives of Neurology, 2009, 66, 571-6.	4.5	183
55	Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain, 2009, 132, 1783-1794.	7.6	612
56	MUTATIONS IN GBA ARE ASSOCIATED WITH FAMILIAL PARKINSON DISEASE SUSCEPTIBILITY AND AGE AT ONSET. Neurology, 2009, 73, 1424-1426.	1.1	142
57	GLUCOCEREBROSIDASE MUTATIONS IN 108 NEUROPATHOLOGICALLY CONFIRMED CASES OF MULTIPLE SYSTEM ATROPHY. Neurology, 2009, 72, 1185-1186.	1.1	60
58	Recommendations on Diagnosis, Treatment, and Monitoring for Gaucher Disease. Journal of Pediatrics, 2009, 155, S10-S18.	1.8	45

#	Article	IF	Citations
59	No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Movement Disorders, 2009, 24, 1519-1523.	3.9	72
60	The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Movement Disorders, 2009, 24, 1571-1578.	3.9	71
61	Parkinsonism in Gaucher's disease type 1: Ten new cases and a review of the literature. Movement Disorders, 2009, 24, 1524-1530.	3.9	28
62	Bell's palsy preceding Parkinson's disease: A caseâ€control study. Movement Disorders, 2009, 24, 1530-1533.	3.9	1
63	Vertical optokinetic nystagmus in Parkinson's disease. Movement Disorders, 2009, 24, 1533-1538.	3.9	4
64	Deep brain stimulation in dystonia: Sonographic monitoring of electrode placement into the globus pallidus internus. Movement Disorders, 2009, 24, 1538-1541.	3.9	22
65	Tremor on smiling. Movement Disorders, 2009, 24, 1542-1545.	3.9	9
66	Hereditary parkinsonism: Parkinson disease lookâ€alikesâ€”An algorithm for clinicians to â€œPARKâ€• genes and beyond. Movement Disorders, 2009, 24, 2042-2058.	3.9	62
67	From Genes to Proteins in Mendelian Parkinson's Disease: An Overview. Anatomical Record, 2009, 292, 1893-1901.	1.4	14
68	Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease. New England Journal of Medicine, 2009, 361, 1651-1661.	27.0	1,747
69	Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology, 2009, 72, 310-316.	1.1	215
70	Genetic susceptibility in Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 597-603.	3.8	37
71	Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiology of Aging, 2009, 30, 1515-1517.	3.1	97
73	Glucosidase-beta variations and Lewy body disorders. Parkinsonism and Related Disorders, 2009, 15, 414-416.	2.2	36
74	Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neuroscience Letters, 2009, 452, 87-89.	2.1	94
75	Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism. NeuroToxicology, 2009, 30, 1127-1132.	3.0	164
77	Parkinson's disease: from monogenic forms to genetic susceptibility factors. Human Molecular Genetics, 2009, 18, R48-R59.	2.9	816
78	Etiology and Pathogenesis of Parkinson Disease. Neurologic Clinics, 2009, 27, 583-603.	1.8	105

#	Article	IF	Citations
79	Association of Glucocerebrosidase Mutations With Dementia With Lewy Bodies. Archives of Neurology, 2009, 66, 578-83.	4.5	168
80	International Study Confirms Glucocerebrosidase Mutations in Parkinson Disease. Neurology Today: an Official Publication of the American Academy of Neurology, 2009, 9, 8.	0.0	0
82	Glucocerebrosidase as a genetic modifier influencing susceptibility and phenotype of Parkinsonâ€™s disease. Future Neurology, 2010, 5, 189-193.	0.5	0
83	Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinsonâ€™s, Huntingtonâ€™s, Alzheimerâ€™s, prions, bactericides, chemical toxicology and others as examples. Archives of Toxicology, 2010, 84, 825-889.	4.2	330
84	Glucocerebrosidase is present in Î±-synuclein inclusions in Lewy body disorders. Acta Neuropathologica, 2010, 120, 641-649.	7.7	169
85	The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders. Current Neurology and Neuroscience Reports, 2010, 10, 190-198.	4.2	131
86	The risk of Parkinson's disease in type 1 Gaucher disease. Journal of Inherited Metabolic Disease, 2010, 33, 167-173.	3.6	182
87	Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach. Neurobiology of Disease, 2010, 39, 229-241.	4.4	67
88	Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease. Movement Disorders, 2010, 25, 1505-1506.	3.9	12
89	Cognitive impairment and dementia in Parkinson's disease. Movement Disorders, 2010, 25, S110-6.	3.9	37
90	Glucocerebrosidase Gene L444P mutation is a risk factor for Parkinson's disease in Chinese population. Movement Disorders, 2010, 25, 1005-1011.	3.9	50
91	Gaucher disease ascertained through a Parkinson's center: Imaging and clinical characterization. Movement Disorders, 2010, 25, 1364-1372.	3.9	77
92	Atypical parkinsonism with apraxia and supranuclear gaze abnormalities in type 1 Gaucher disease. Expanding the spectrum: Case report and literature review. Movement Disorders, 2010, 25, 1506-1509.	3.9	21
93	Rare and serious cardiac side effects during ropinirole titration. Movement Disorders, 2010, 25, 1509-1510.	3.9	8
94	Valproateâ€induced reversible hemichorea. Movement Disorders, 2010, 25, 1511-1512.	3.9	15
95	Facial tic associated with lamotrigine in adults. Movement Disorders, 2010, 25, 1512-1513.	3.9	10
96	Primary progressive freezing gait in a patient with COâ€induced parkinsonism. Movement Disorders, 2010, 25, 1513-1515.	3.9	14
97	Multiple system atrophy and colon inertia. Movement Disorders, 2010, 25, 1515-1516.	3.9	0

#	Article	IF	Citations
98	Multipleâ€system atrophy presenting with low rectal compliance and bowel pain. Movement Disorders, 2010, 25, 1516-1518.	3.9	3
99	Changes in apraxia after deep brain stimulation of the nucleus basalis Meynert in a patient with Parkinson dementia syndrome. Movement Disorders, 2010, 25, 1519-1520.	3.9	43
100	Congenital mirror movements in Parkinson's disease: Clinical and neurophysiological observations. Movement Disorders, 2010, 25, 1520-1523.	3.9	6
101	Parkinsonism and cognitive decline in a fragile X mosaic male. Movement Disorders, 2010, 25, 1523-1524.	3.9	12
102	Olfactory dysfunction in Japanese patients with idiopathic REM sleep behavior disorder: Comparison of data using the university of Pennsylvania smell identification test and odor stick identification test for Japanese. Movement Disorders, 2010, 25, 1524-1526.	3.9	11
103	Association of the glucocerebrosidase N370S allele with Parkinsonâ€™s disease in two separate Chinese Han populations of mainland China. European Journal of Neurology, 2010, 17, 1476-1478.	3.3	37
104	Optimal therapy in Gaucher disease. Therapeutics and Clinical Risk Management, 2010, 6, 315.	2.0	13
105	Glucocerebrosidase Gene Mutations and Parkinsonism. , 2010, , 555-557.		0
106	Autosomal recessive mutations in the development of Parkinsonâ€™s disease. Biomarkers in Medicine, 2010, 4, 713-721.	1.4	12
107	Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Human Molecular Genetics, 2010, 19, 3771-3781.	2.9	93
109	Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa. Neuroscience Letters, 2010, 477, 57-60.	2.1	30
110	Association between GBA L444P mutation and sporadic Parkinson's disease from Mainland China. Neuroscience Letters, 2010, 469, 256-259.	2.1	56
111	POLG1 polyglutamine tract variants associated with Parkinson's disease. Neuroscience Letters, 2010, 477, 1-5.	2.1	47
112	Mutational analysis of GIGYF2, ATP13A2 and GBA genes in Brazilian patients with early-onset Parkinson's disease. Neuroscience Letters, 2010, 485, 121-124.	2.1	26
113	Multiplexed resequencing analysis to identify rare variants in pooled DNA with barcode indexing using next-generation sequencer. Journal of Human Genetics, 2010, 55, 448-455.	2.3	13
114	Parkinson's Disease: Genetics and Pathogenesis. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 193-222.	22.4	654
115	The incidence of Parkinsonism in patients with type 1 Gaucher disease: Data from the ICGG Gaucher Registry. Blood Cells, Molecules, and Diseases, 2011, 46, 95-102.	1.4	124
116	Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends in Molecular Medicine, 2011, 17, 485-493.	6.7	146

#	Article	IF	Citations
117	Accumulation and distribution of Î±-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Molecular Genetics and Metabolism, 2011, 102, 436-447.	1.1	130
118	Aggregation of Î±-synuclein in brain samples from subjects with glucocerebrosidase mutations. Molecular Genetics and Metabolism, 2011, 104, 185-188.	1.1	67
119	The enigma of the E326K mutation in acid Î²-glucocerebrosidase. Molecular Genetics and Metabolism, 2011, 104, 35-38.	1.1	46
120	Glucocerebrosidase mutations in diffuse Lewy body disease. Parkinsonism and Related Disorders, 2011, 17, 55-57.	2.2	43
121	Genetic players in multiple system atrophy: unfolding the nature of the beast. Neurobiology of Aging, 2011, 32, 1924.e5-1924.e14.	3.1	39
122	Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders. International Journal of Alzheimer's Disease, 2011, 2011, 1-18.	2.0	7
123	DNA methylation in neurodegenerative disorders: a missing link between genome and environment?. Clinical Genetics, 2011, 80, 1-14.	2.0	53
124	A Genomeâ€Wide Linkage Screen in the Amish with Parkinson Disease Points to Chromosome 6. Annals of Human Genetics, 2011, 75, 351-358.	0.8	9
125	Parkinson's disease and cancer: two wars, one front. Nature Reviews Cancer, 2011, 11, 813-823.	28.4	146
126	What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease. Physiological Reviews, 2011, 91, 1161-1218.	28.8	515
127	Decades of delayed diagnosis in 4 levodopaâ€responsive youngâ€onset monogenetic parkinsonism patients. Movement Disorders, 2011, 26, 1337-1340.	3.9	4
128	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. Movement Disorders, 2011, 26, 1348-1352.	3.9	18
129	Osteopontin polymorphic susceptibility factor for Parkinson's disease among patients with Gaucher disease. Movement Disorders, 2011, 26, 1341-1343.	3.9	6
130	Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease. Movement Disorders, 2011, 26, 1344-1347.	3.9	17
131	Milestones in PD genetics. Movement Disorders, 2011, 26, 1042-1048.	3.9	147
132	Acid Î²â€glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter Î±â€synuclein processing. Annals of Neurology, 2011, 69, 940-953.	5.3	276
133	Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Human Molecular Genetics, 2011, 20, 202-210.	2.9	258
134	Î±-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher Diseases. Journal of Biological Chemistry, 2011, 286, 28080-28088.	3.4	160

#	Article	IF	Citations
135	A Deficiency of Ceramide Biosynthesis Causes Cerebellar Purkinje Cell Neurodegeneration and Lipofuscin Accumulation. PLoS Genetics, 2011, 7, e1002063.	3.5	137
136	Genetics of Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a008888-a008888.	6.2	1,026
137	Association of Common Variants in the Glucocerebrosidase Gene with High Susceptibility to Parkinson's Disease among Chinese. Chinese Journal of Physiology, 2012, 55, 398-404.	1.0	11
138	Pantothenate Kinase-Associated Neurodegeneration. Current Drug Targets, 2012, 13, 1182-1189.	2.1	13
139	The link between the GBA gene and parkinsonism. Lancet Neurology, The, 2012, 11, 986-998.	10.2	475
140	The cognitive profile of type 1 Gaucher disease patients. Journal of Inherited Metabolic Disease, 2012, 35, 1093-1099.	3.6	17
141	Glucocerebrosidase gene variants in parkinsonian patients with Machado Joseph/spinocerebellar ataxia 3. Parkinsonism and Related Disorders, 2012, 18, 185-190.	2.2	17
142	A DNA resequencing array for genes involved in Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2012, 18, 386-390.	2.2	7
143	Association of mutations in the glucocerebrosidase gene with Parkinson disease in a Korean population. Neuroscience Letters, 2012, 514, 12-15.	2.1	49
144	Glucocerebrosidase L444P mutation confers genetic risk for Parkinsonâ€™s disease in central China. Behavioral and Brain Functions, 2012, 8, 57.	3.3	33
145	Sphingolipids: Critical players in Alzheimerâ€™s disease. Progress in Lipid Research, 2012, 51, 378-393.	11.6	143
146	Glucocerebrosidase Involvement in Parkinson Disease and Other Synucleinopathies. Frontiers in Neurology, 2012, 3, 65.	2.4	15
147	The neuropathology of genetic Parkinson's disease. Movement Disorders, 2012, 27, 831-842.	3.9	229
148	Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Movement Disorders, 2012, 27, 393-399.	3.9	144
149	The Association Between ÃŸ-Glucocerebrosidase Mutations and Parkinsonism. Current Neurology and Neuroscience Reports, 2013, 13, 368.	4.2	32
150	Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling. Genetics in Medicine, 2013, 15, 146-149.	2.4	103
151	Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. Movement Disorders, 2013, 28, 747-754.	3.9	88
152	Lipidomics as a Principal Tool for Advancing Biomedical Research. Journal of Genetics and Genomics, 2013, 40, 375-390.	3.9	110

#	Article	IF	Citations
153	Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Annals of Medicine, 2013, 45, 511-521.	3.8	107
154	Immunotherapy for neurodegenerative diseases: Focus on Î±-synucleinopathies. , 2013, 138, 311-322.		115
155	Gaucher Disease and Its Treatment Options. Annals of Pharmacotherapy, 2013, 47, 1182-1193.	1.9	88
156	Evoked potentails and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience. Journal of Inherited Metabolic Disease, 2013, 36, 1025-1037.	3.6	14
157	A Biological Perspective of CSF Lipids as Surrogate Markers for Cognitive Status in HIV. Journal of NeuroImmune Pharmacology, 2013, 8, 1136-1146.	4.1	14
158	Unfolded protein response in Gaucher disease: from human to Drosophila. Orphanet Journal of Rare Diseases, 2013, 8, 140.	2.7	88
159	Genetics and iron in the systems biology of Parkinsonâ€™s disease and some related disorders. Neurochemistry International, 2013, 62, 637-652.	3.8	56
160	Mutations in GBA and risk of Parkinsonâ€™s disease: a meta-analysis based on 25 case-control studies. Neurological Research, 2013, 35, 873-878.	1.3	21
161	A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research. DMM Disease Models and Mechanisms, 2013, 6, 1316-24.	2.4	31
162	Glucocerebrosidase, a new player changing the old rules in Lewy body diseases. Biological Chemistry, 2013, 394, 807-818.	2.5	14
164	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	9.0	374
165	Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid. PLoS ONE, 2014, 9, e101453.	2.5	23
166	Glucocerebrosidase Gene Mutations Associated with Parkinson's Disease: A Meta-Analysis in a Chinese population. PLoS ONE, 2014, 9, e115747.	2.5	32
167	Original article The key role of sphingosine kinases in the molecular mechanism of neuronal cell survival and death in an experimental model of Parkinsonâ€™s disease. Folia Neuropathologica, 2014, 3, 260-269.	1.2	51
168	The genetics of Parkinson’s disease: review of current and emerging candidates. Journal of Parkinsonism and Restless Legs Syndrome, 2014, , 63.	0.8	1
169	Multiple System Atrophy: Genetic or Epigenetic?. Experimental Neurobiology, 2014, 23, 277-291.	1.6	28
170	Carbohydrates as Drugs. Topics in Medicinal Chemistry, 2014, , .	0.8	6
171	Iminosugars: Therapeutic Applications and Synthetic Considerations. Topics in Medicinal Chemistry, 2014, , 23-51.	0.8	15

#	Article	IF	Citations
172	Comparison of Parkinson Risk in Ashkenazi Jewish Patients With Gaucher Disease andGBAHeterozygotes. JAMA Neurology, 2014, 71, 752.	9.0	172
173	Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice. Acta Neuropathologica Communications, 2014, 2, 20.	5.2	58
174	Glucocerebrosidase is shaking up the synucleinopathies. Brain, 2014, 137, 1304-1322.	7.6	128
175	Gaucher disease: haematological presentations and complications. British Journal of Haematology, 2014, 165, 427-440.	2.5	81
176	Significant study of population stratification, sensitivity analysis and trim and fill analyses on GBA mutation and parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 96-102.	1.7	11
177	Neuroinflammation and Î±-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Molecular Genetics and Metabolism, 2014, 111, 152-162.	1.1	94
178	Gaucher Disease and Bone Manifestations. Calcified Tissue International, 2014, 95, 477-494.	3.1	53
179	Glucocerebrosidase mutations in Thai patients with Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 986-991.	2.2	35
180	Î±-Synuclein rs356219 polymorphisms in patients with Gaucher disease and Parkinson disease. Neuroscience Letters, 2014, 580, 104-107.	2.1	2
181	Glycobiology of the Nervous System. Advances in Neurobiology, 2014, , .	1.8	9
182	The significance of GBA for Parkinson's disease. Journal of Inherited Metabolic Disease, 2014, 37, 643-648.	3.6	36
183	Cerebrospinal fluid lysosomal enzymes and alphaâ€synuclein in Parkinson's disease. Movement Disorders, 2014, 29, 1019-1027.	3.9	223
184	Studies of glucocerebrosidase provide new therapeutic targets for parkinsonism. Future Neurology, 2014, 9, 407-409.	0.5	0
185	Lysosomal integral membrane protein-2: A new player in lysosome-related pathology. Molecular Genetics and Metabolism, 2014, 111, 84-91.	1.1	63
186	Correction of lysosomal dysfunction as a therapeutic strategy for neurodegenerative diseases. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3001-3005.	2.2	10
187	Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry. American Journal of Hematology, 2015, 90, S12-8.	4.1	93
188	Color Discrimination in Patients with Gaucher Disease and Parkinson Disease. Journal of Parkinson's Disease, 2015, 5, 525-531.	2.8	2
189	Visualization of Active Glucocerebrosidase in Rodent Brain with High Spatial Resolution following In Situ Labeling with Fluorescent Activity Based Probes. PLoS ONE, 2015, 10, e0138107.	2.5	28

#	Article	IF	Citations
190	Clinical manifestations and management of Gaucher disease. Clinical Cases in Mineral and Bone Metabolism, 2015, 12, 157-64.	1.0	51
191	Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinsonâ€™s disease. Journal of Human Genetics, 2015, 60, 85-90.	2.3	34
192	GBA mutations and Parkinson disease: When genotype meets phenotype. Neurology, 2015, 84, 866-867.	1.1	9
193	Fluorescence-Quenched Substrates for Live Cell Imaging of Human Glucocerebrosidase Activity. Journal of the American Chemical Society, 2015, 137, 1181-1189.	13.7	59
194	Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends in Genetics, 2015, 31, 140-149.	6.7	193
195	Genetics of Mendelian Forms of Parkinsonâ€™s Disease. , 2015, , 3-18.		1
196	Glucocerebrosidase activity in Parkinsonâ€™s disease with and withoutGBAmutations. Brain, 2015, 138, 2648-2658.	7.6	326
197	Gaucher-Associated Parkinsonism. Cellular and Molecular Neurobiology, 2015, 35, 755-761.	3.3	22
198	Understanding and managing parkinsonism in patients with glucocerebrosidase mutations. Expert Opinion on Orphan Drugs, 2015, 3, 549-562.	0.8	1
199	Selective loss of glucocerebrosidase activity in sporadic Parkinsonâ€™s disease and dementia with Lewy bodies. Molecular Neurodegeneration, 2015, 10, 15.	10.8	120
200	Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiology of Aging, 2015, 36, 3306-3313.	3.1	89
201	Multisystem Lewy body disease and the other parkinsonian disorders. Nature Genetics, 2015, 47, 1378-1384.	21.4	49
202	Genotypeâ€“Phenotype Correlations in Parkinson Disease. , 2015, , 259-285.		1
203	The emergence of Parkinson disease among patients with Gaucher disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 249-259.	4.7	12
204	Genetic Convergence of Parkinsonâ€™s Disease and Lysosomal Storage Disorders. Molecular Neurobiology, 2015, 51, 1554-1568.	4.0	22
205	Combination therapies: The next logical Step for the treatment of synucleinopathies?. Movement Disorders, 2016, 31, 225-234.	3.9	45
206	The relationship between glucocerebrosidase mutations and Parkinson disease. Journal of Neurochemistry, 2016, 139, 77-90.	3.9	167
207	Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiology of Aging, 2016, 41, 200.e1-200.e5.	3.1	96

#	Article	IF	Citations
208	Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Expert Review of Proteomics, 2016, 13, 471-479.	3.0	51
209	The contribution of mutantGBAto the development of Parkinson disease inDrosophila. Human Molecular Genetics, 2016, 25, ddw129.	2.9	60
210	New Directions in Gaucher Disease. Human Mutation, 2016, 37, 1121-1136.	2.5	25
211	Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges. Movement Disorders, 2016, 31, 1433-1443.	3.9	34
212	Glycobiology of Human Milk in Health and Disease. , 2016, , 233-250.		0
213	Lysosomal Dysfunction and Î±â€Synuclein Aggregation in Parkinson's Disease: Diagnostic Links. Movement Disorders, 2016, 31, 791-801.	3.9	125
214	Resequencing analysis of five Mendelian genes andÂthe top genes from genome-wide association studies in Parkinsonâ€™s Disease. Molecular Neurodegeneration, 2016, 11, 29.	10.8	70
215	Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden. Neurobiology of Aging, 2016, 45, 212.e5-212.e11.	3.1	50
216	GBA Mutations Are Associated With Earlier Onset and Male Sex in Dementia With Lewy Bodies. Movement Disorders, 2016, 31, 1066-1070.	3.9	34
217	Genes associated with Parkinson's disease: regulation of autophagy and beyond. Journal of Neurochemistry, 2016, 139, 91-107.	3.9	88
218	Glucocerebrosidase and parkinsonism: lessons to learn. Journal of Neurology, 2016, 263, 1033-1044.	3.6	6
219	Mutations of glucocerebrosidase gene and susceptibility to Parkinsonâ€™s disease: An updated meta-analysis in a European population. Neuroscience, 2016, 320, 239-246.	2.3	33
220	Comprehensive untargeted lipidomic analysis using coreâ€“shell C30 particle column and high field orbitrap mass spectrometer. Journal of Chromatography A, 2016, 1440, 123-134.	3.7	117
221	Endocytic membrane trafficking and neurodegenerative disease. Cellular and Molecular Life Sciences, 2016, 73, 1529-1545.	5.4	130
222	From rare to common and back again: 60years of lysosomal dysfunction. Molecular Genetics and Metabolism, 2016, 117, 53-65.	1.1	17
223	Mutations in the glucocerebrosidase gene are common in patients with Parkinson's disease from Eastern Canada. International Journal of Neuroscience, 2016, 126, 415-421.	1.6	27
224	Lipid profiling of parkinâ€mutant human skin fibroblasts. Journal of Cellular Physiology, 2017, 232, 3540-3551.	4.1	39
225	The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease. Neuron, 2017, 93, 737-746.	8.1	127

#	Article	IF	Citations
227	Epigenetics in Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2017, 978, 363-390.	1.6	50
228	The Role of Astrocyte Dysfunction in Parkinsonâ€™s Disease Pathogenesis. Trends in Neurosciences, 2017, 40, 358-370.	8.6	425
229	Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Human Molecular Genetics, 2017, 26, 2603-2615.	2.9	37
230	Sphingosine 1-phosphate â€“ A double edged sword in the brain. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1573-1582.	2.6	61
231	The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. Scientific Reports, 2017, 7, 12702.	3.3	62
232	Serum lipid alterations in GBA-associated Parkinson's disease. Parkinsonism and Related Disorders, 2017, 44, 58-65.	2.2	73
233	The role of epigenetics in lysosomal storage disorders: Uncharted territory. Molecular Genetics and Metabolism, 2017, 122, 10-18.	1.1	41
234	Altered Differentiation Potential of Gaucherâ€™s Disease iPSC Neuronal Progenitors due to Wnt/Î²-Catenin Downregulation. Stem Cell Reports, 2017, 9, 1853-1867.	4.8	42
235	Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature. Movement Disorders, 2017, 32, 1504-1523.	3.9	229
236	Parkinsonâ€™s Disease: Basic Pathomechanisms and a Clinical Overview. Advances in Neurobiology, 2017, 15, 55-92.	1.8	2
237	Gaucher disease: Progress and ongoing challenges. Molecular Genetics and Metabolism, 2017, 120, 8-21.	1.1	112
238	Glucocerebrosidase Gene Mutations and Parkinsonismâ˜†. , 2017, , .		0
239	Glucocerebrosidase gene variants are accumulated in idiopathic REM sleep behavior disorder. Parkinsonism and Related Disorders, 2018, 50, 94-98.	2.2	23
240	Molecular regulations and therapeutic targets of Gaucher disease. Cytokine and Growth Factor Reviews, 2018, 41, 65-74.	7.2	13
241	A novel p.L216I mutation in the glucocerebrosidase gene is associated with Parkinsonâ€™s disease in Han Chinese patients. Neuroscience Letters, 2018, 674, 66-69.	2.1	6
242	Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and metaâ€analyses. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 232-241.	1.7	49
243	The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein. Neurobiology of Disease, 2018, 110, 68-81.	4.4	38
244	A Meta-Analysis of GBA-Related Clinical Symptoms in Parkinsonâ€™s Disease. Parkinson's Disease, 2018, 2018, 1-7.	1.1	29

#	Article	IF	Citations
245	Converging pathways in neurodegeneration, from genetics to mechanisms. Nature Neuroscience, 2018, 21, 1300-1309.	14.8	325
246	Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum. Molecular Genetics and Metabolism Reports, 2018, 17, 69-72.	1.1	4
247	Self-report data as a tool for subtype identification in genetically-defined Parkinsonâ€™s Disease. Scientific Reports, 2018, 8, 12992.	3.3	12
248	Proteomics and lipidomics in the human brain. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 150, 285-302.	1.8	7
249	Integrated Genetic Analysis of Racial Differences of Common GBA Variants in Parkinson's Disease: A Meta-Analysis. Frontiers in Molecular Neuroscience, 2018, 11, 43.	2.9	71
250	Î±-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Molecular Neurodegeneration, 2018, 13, 1.	10.8	143
251	Parkinsonâ€™s Disease and Other Synucleinopathies. , 2018, , 117-143.		0
252	The motor and cognitive features of Parkinsonâ€™s disease in patients with concurrent Gaucher disease over 2 years: a case series. Journal of Neurology, 2018, 265, 1789-1794.	3.6	11
253	Augmented frontal cortex diacylglycerol levels in Parkinsonâ€™s disease and Lewy Body Disease. PLoS ONE, 2018, 13, e0191815.	2.5	47
254	Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. European Journal of Medical Genetics, 2019, 62, 65-69.	1.3	49
255	Approach to Assessment of Parkinson Disease with Emphasis on Genetic Testing. Medical Clinics of North America, 2019, 103, 1055-1075.	2.5	9
256	Glucocerebrosidase and its relevance to Parkinson disease. Molecular Neurodegeneration, 2019, 14, 36.	10.8	197
257	Progress in the genetic analysis of Parkinsonâ€™s disease. Human Molecular Genetics, 2019, 28, R215-R218.	2.9	27
258	Restoring autophagic flux attenuates cochlear spiral ganglion neuron degeneration by promoting TFEB nuclear translocation via inhibiting MTOR. Autophagy, 2019, 15, 998-1016.	9.1	35
259	Evolution of prodromal parkinsonian features in a cohort ofGBAmutation-positive individuals: a 6-year longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1091-1097.	1.9	44
260	SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease. Movement Disorders, 2019, 34, 1333-1344.	3.9	21
261	Ceramides in Parkinsonâ€™s Disease: From Recent Evidence to New Hypotheses. Frontiers in Neuroscience, 2019, 13, 330.	2.8	41
262	GBA, Gaucher Disease, and Parkinsonâ€™s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells, 2019, 8, 364.	4.1	187

#	Article	IF	Citations
263	GBA mutations p.N370S and p.L444P are associated with Parkinson's disease in patients from Northern Brazil. Arquivos De Neuro-Psiquiatria, 2019, 77, 73-79.	0.8	9
264	Emerging links between pediatric lysosomal storage diseases and adult parkinsonism. Movement Disorders, 2019, 34, 614-624.	3.9	37
265	GBA1 mutations: Prospects for exosomal biomarkers in Î±-synuclein pathologies. Molecular Genetics and Metabolism, 2020, 129, 35-46.	1.1	11
266	Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics. Parkinsonism and Related Disorders, 2020, 73, 60-71.	2.2	85
267	Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. Progress in Neurobiology, 2020, 185, 101732.	5.7	159
268	LRRK2 and the Endolysosomal System in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 1271-1291.	2.8	52
269	Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease. Biomolecules, 2020, 10, 1630.	4.0	8
270	The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinsonâ€™s Disease. Biomolecules, 2020, 10, 912.	4.0	18
271	The S1Pâ€“S1PR Axis in Neurological Disordersâ€”Insights into Current and Future Therapeutic Perspectives. Cells, 2020, 9, 1515.	4.1	30
272	Synucleinopathies: Where we are and where we need to go. Journal of Neurochemistry, 2020, 153, 433-454.	3.9	62
273	The biochemical basis of interactions between Glucocerebrosidase and alphaâ€synuclein in GBA1 mutation carriers. Journal of Neurochemistry, 2020, 154, 11-24.	3.9	10
274	Inhibition of sphingolipid synthesis improves outcomes and survival in GARP mutant wobbler mice, a model of motor neuron degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10565-10574.	7.1	33
275	Enzymes for pharmaceutical and therapeutic applications. Biotechnology and Applied Biochemistry, 2020, 67, 586-601.	3.1	52
276	Pathways of protein synthesis and degradation in PD pathogenesis. Progress in Brain Research, 2020, 252, 217-270.	1.4	5
277	MitophAging: Mitophagy in Aging and Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 239.	3.7	87
278	Hijacking Endocytosis and Autophagy in Extracellular Vesicle Communication: Where the Inside Meets the Outside. Frontiers in Cell and Developmental Biology, 2020, 8, 595515.	3.7	22
279	Cross-talks among GBA mutations, glucocerebrosidase, and Î±-synuclein in GBA-associated Parkinsonâ€™s disease and their targeted therapeutic approaches: a comprehensive review. Translational Neurodegeneration, 2021, 10, 4.	8.0	48
280	Aberrant proteins expressed in skin fibroblasts of Parkinson's disease patients carrying heterozygous variants of glucocerebrosidase and parkin genes. Biomedical Reports, 2021, 14, 36.	2.0	1

#	Article	IF	Citations
281	Advancing Personalized Medicine in Common Forms of Parkinsonâ€™s Disease through Genetics: Current Therapeutics and the Future of Individualized Management. Journal of Personalized Medicine, 2021, 11, 169.	2.5	6
282	Functional Connectivity Analysis in Heterozygous Glucocerebrosidase Mutation Carriers. Journal of Parkinson's Disease, 2021, 11, 559-568.	2.8	5
283	â€œJanus-Facedâ€•Î±-Synuclein: Role in Parkinsonâ€™s Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 673395.	3.7	8
284	Bioinformatics analysis and identification of genes and molecular pathways involved in Parkinsonâ€™s disease in patients with mutations in the glucocerebrosidase gene. NeuroReport, 2021, 32, 918-924.	1.2	1
285	Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models. Frontiers in Neurology, 2021, 12, 681369.	2.4	10
286	Mini review â€“ The role of Glucocerebrosidase and Progranulin as possible targets in the treatment of Parkinson's disease. Revue Neurologique, 2021, 177, 1082-1089.	1.5	4
287	Recalling the pathology of Parkinson's disease; lacking exact figure of prevalence and genetic evidence in Asia with an alarming outcome: A time to stepâ€up. Clinical Genetics, 2021, 100, 659-677.	2.0	8
288	Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Frontotemporal Dementias: Different Manifestations of Protein Misfolding. , 2008, , 123-131.		1
289	Glycoconjugate Changes in Aging and Age-Related Diseases. Advances in Neurobiology, 2014, 9, 415-447.	1.8	6
290	The Interplay Between Proteostasis Systems and Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2020, 1233, 223-236.	1.6	6
291	Lysosomal Storage Diseases. , 2012, , 403-451.		655
292	Lipid Pathway Alterations in Parkinson's Disease Primary Visual Cortex. PLoS ONE, 2011, 6, e17299.	2.5	142
293	Convergence of miRNA Expression Profiling, Î±-Synuclein Interacton and GWAS in Parkinson's Disease. PLoS ONE, 2011, 6, e25443.	2.5	235
294	Long-Term Outcomes of Genetic Parkinsonâ€™s Disease. Journal of Movement Disorders, 2020, 13, 81-96.	1.3	21
295	Pathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinsonâ€™s Disease. , 0, , 45-64.		5
296	Pharmacogenetics of Parkinsonâ€™s Disease â€“ Through Mechanisms of Drug Actions. Current Genomics, 2014, 14, 568-577.	1.6	16
297	Role of Genes and Treatments for Parkinsonâ€™s Disease. The Open Biology Journal, 2020, 8, 47-65.	0.5	4
298	Patient-specific pluripotent stem cell-based Parkinsonâ€™s disease models showing endogenous alpha-synuclein aggregation. BMB Reports, 2019, 52, 349-359.	2.4	11

#	Article	IF	Citations
299	New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. Neuropharmacology, 2022, 202, 108822.	4.1	33
300	Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease. Yearbook of Neurology and Neurosurgery, 2010, 2010, 104-105.	0.0	0
302	The Genetics of Alzheimerâ€™s Disease and Parkinsonâ€™s Disease. Advances in Neurobiology, 2011, , 695-755.	1.8	7
303	Role of Lysosomal Enzymes in Parkinsonâ€™s Disease: Lesson from Gaucherâ€™s Disease. , 0, , .		0
304	The Sphingolipidoses. , 2016, , 659-682.		2
306	Preventing Parkinsonâ€™s Disease: An Environmental Agenda. Journal of Parkinson's Disease, 2022, 12, 45-68.	2.8	45
307	Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics: Targets and Therapy, 2009, 3, 407-17.	3.2	35
308	Gaucher disease: insights from a rare Mendelian disorder. Discovery Medicine, 2012, 14, 273-81.	0.5	80
309	Parkinson's Disease Associated with GBA Gene Mutations: Molecular Aspects and Potential Treatment Approaches. Acta Naturae, 2021, 13, 70-78.	1.7	1
310	Parkinsonâ€™s Disease Associated with GBA Gene Mutations: Molecular Aspects and Potential Treatment Approaches. Acta Naturae, 2021, 13, 70-78.	1.7	6
311	Modifying Chromatography Conditions for Improved Unknown Feature Identification in Untargeted Metabolomics. Analytical Chemistry, 2021, 93, 15840-15849.	6.5	13
312	Gaucher disease â€“ more than just a rare lipid storage disease. Journal of Molecular Medicine, 2022, 100, 499-518.	3.9	13
313	Evaluation of Ectopic Mitochondrial DNA in HeLa Cells. Current Issues in Molecular Biology, 2022, 44, 1215-1223.	2.4	0
314	Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinsonâ€™s Disease: Pathogenesis and Therapeutic Implications. Frontiers in Aging Neuroscience, 2022, 14, 851135.	3.4	7
315	GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells, 2022, 11, 1261.	4.1	61
316	The Role of Sphingosine-1-Phosphate in Neurodegenerative Diseases. Russian Journal of Bioorganic Chemistry, 2021, 47, 1155-1171.	1.0	0
317	Mitochondrial Function and Parkinsonâ€™s Disease: From the Perspective of the Electron Transport Chain. Frontiers in Molecular Neuroscience, 2021, 14, 797833.	2.9	25
327	Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics: Targets and Therapy, 2009, 3, 407.	3.2	24

#	Article	IF	Citations
328	Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism. International Journal of Molecular Sciences, 2022, 23, 5842.	4.1	8
329	Crosstalk of organelles in Parkinsonâ€™s disease â€“ MiT family transcription factors as central players in signaling pathways connecting mitochondria and lysosomes. Molecular Neurodegeneration, 2022, 17, .	10.8	8
330	Molecular genetics of Parkinsonâ€™s disease: Contributions and global trends. Journal of Human Genetics, 2023, 68, 125-130.	2.3	39
331	Î²-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration. Cells, 2022, 11, 2343.	4.1	8
332	Oxidative stress and synaptic dysfunction in rodent models of Parkinson's disease. Neurobiology of Disease, 2022, 173, 105851.	4.4	17
335	A class of anti-inflammatory lipids decrease with aging in the central nervous system. Nature Chemical Biology, 2023, 19, 187-197.	8.0	4
336	Autophagy and Its Association with Genetic Mutations in Parkinson Disease. Medical Science Monitor, 0, 28, .	1.1	2
337	Classification of <scp>GBA1</scp> Variants in Parkinson's Disease: The <scp>GBA1â€PD</scp> Browser. Movement Disorders, 2023, 38, 489-495.	3.9	18
338	Carbohydrases: a class of all-pervasive industrial biocatalysts. , 2023, , 497-523.		2
339	a-Synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy. PLoS ONE, 2023, 18, e0277602.	2.5	1
341	Mechanisms of Glucocerebrosidase Dysfunction in Parkinsonâ€™s Disease. Journal of Molecular Biology, 2023, 435, 168023.	4.2	7
342	Neuronopathic Gaucher disease models reveal defects in cell growth promoted by Hippo pathway activation. Communications Biology, 2023, 6, .	4.4	0
343	Glycolipids in Parkinson's disease: beyond neuronal function. FEBS Open Bio, 0, , .	2.3	0
344	GBA1 in Parkinsonâ€™s disease: variant detection and pathogenicity scoring matters. BMC Genomics, 2023, 24, .	2.8	0
345	Genes and dietary metals in Parkinson's disease. , 2023, , 603-630.		0
346	The ANeED study â€“ ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
347	Lessons and future directions for GBA1-targeting therapies. Lancet Neurology, The, 2023, 22, 644-645.	10.2	0
348	Lewy Body Dementia: An Overview of Promising Therapeutics. Current Neurology and Neuroscience Reports, 2023, 23, 581-592.	4.2	1

#	Article	IF	Citations
349	Axonal Transport of Lysosomes Is Unaffected in Glucocerebrosidase-Inhibited iPSC-Derived Forebrain Neurons. ENeuro, 2023, 10, ENEURO.0079-23.2023.	1.9	0
350	Post-translational modification and mitochondrial function in Parkinsonâ€™s disease. Frontiers in Molecular Neuroscience, 0, 16, .	2.9	0
351	The Potentiality of Natural Products and Herbal Medicine as Novel Medications for Parkinsonâ€™s Disease: A Promising Therapeutic Approach. International Journal of Molecular Sciences, 2024, 25, 1071.	4.1	0
352	Synthesis, crystal structure investigation and computational studies binding of (7S,8R)-7-acetyl-8-(4-chlorophenyl)-3-(ethylthio)-1,6-dimethyl-7,8-dihydroisoquinoline-4-carbonitrile with monoamine oxidase B. Journal of Molecular Structure, 2024, 1307, 137974.	3.6	0
353	DJ-1 protects cell death from a mitochondrial oxidative stress due to GBA1 deficiency. Genes and Genomics, 2024, 46, 519-529.	1.4	0